[Hormonal therapy for benign prostatic hyperplasia].
Sakai
Hideki
H
Department of Urology, Nagasaki University School of Medicine.
Kanetake
Hiroshi
H
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001378:Azasteroids / Q000494:pharmacology / Q000627:therapeutic use; D003864:Depression, Chemical; D013196:Dihydrotestosterone / Q000378:metabolism; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011467:Prostate / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D001378:Azasteroids; D004791:Enzyme Inhibitors; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D013739:Testosterone; D018120:Finasteride; D000068538:Dutasteride